Fig 1. Mechanism of action of ALN-EP4a conjugate. Step 1):
Reversibly conjugate ALN with EP4a and systemically administer the compound.
Step 2): ALN binds to bone mineral and "delivers" EP4a to bone site. Local hydrolytic enzymes in the bone environment cleave the conjugation link to liberate EP4a.
Step 3): EP4a is freed to stimulate bone formation, while ALN remains bound to bone.
receptor subtype. 5 However, the use of PGE2 as a therapeutic agent is limited by metabolic instability, an extremely short half-life in vivo and intolerable side effects (at least in part due to its action on the other EP receptors (EP1, EP2 and EP3)).
We originally postulated that conjugation of PGE2 through metabolically hydrolysable linkers to bisphosphonate antiresorptive compounds might mitigate the issues seen with PGE2 dosing by taking advantage of the bone-directing effects of the bisphosphonate, allowing for the slow release of PGE2 at its site of action and thus limiting systemic exposure. The use of bisphosphonates to target drugs to bone has been widely explored 6 and in particular to deliver antitumor agents to bone. 7 In our previous studies some success was achieved in preparing conjugates (for example, compound 4, Fig. 2 ) using novel but biologically ineffective bisphosphonate carriers. Compound 4 was shown to be well tolerated in rats (up to 100 mg/kg), to be preferentially taken up into bone, to slowly release the PGE2 component and to provide enhanced efficacy in promoting bone growth relative to an equivalent dose of PGE2 itself. 4 However, owing to the instability of PGE2 we were unable to prepare conjugates with the preferred, bioactive bisphosphonates such as alendronic acid with the intention of generating a compound with dual bone resorption inhibitor/bone growth stimulating properties. It was thought that preparation of these dual action conjugates would require a new synthetic approach to generating the conjugates and/or more stable analogs of PGE2.
Subsequently a series of more stable and selective EP4 receptor agonists (exemplified by compounds 5 8 and 6 9 ) (Fig. 2) were identified that are at least as potent and efficacious as PGE2 at the EP4 receptor. Unfortunately, while EP4-selective agonists were found to be effective in stimulating bone growth in rats 10 , they still retained some undesirable gastrointestinal side effects making them likely unsuitable for development as chronic therapies for osteoporosis. Compounds such as 5 and 6 are much more chemically stable and accessible than PGE2 and they have considerably longer systemic half-lives in vivo and thus they could meet the above-noted conditions necessary to prepare the next generation of bone-targeting conjugate.
The goal of this work was to prepare conjugates of both the EP4 agonist acid 5 and tetrazole 6 with the bioactive bisphosphonate alendronic acid 1 and to evaluate their in vivo uptake and release from bone. Such conjugates would need to be relatively stable in the blood steam, survive intact in the systemic circulation long enough to bind efficiently with bone and then to release the two active components slowly over time. Our preferred half-life for release was on the order of 4-7 days, similar to that previously found for the efficacious conjugate 4 and so that once weekly dosing could be supported. The conjugates themselves would need to be well tolerated and compatible with intravenous (IV) dosing.
Results and discussion
The obvious points of connection to attach 5 or 6 to 1, through a slowly hydrolysable linker that will liberate the EP4 agonists intact, are through the C-15 hydroxyl of either compound, the acid moiety of 5 or the tetrazole moiety of 6. It is known (and demonstrated in the previous pro-drug studies) that the acidic functionality and free 15-(R)-hydroxyl group are both required for biological activity at the EP receptors 11 and thus the conjugates themselves were not anticipated to manifest any EP activity in vivo prior to cleavage. As our previous study demonstrated 4 that a simple amide coupling between the PGE2 and bisphosphonate 1 yielded a conjugate that was too robust to allow for liberation of PGE2 once bound to bone, we began a program to prepare carbamate based linkers that should be chemically stable but would hopefully undergo faster cleavage in vivo.
A conjugate linked through the C-15 hydroxyl of 5 was prepared from ester 7, first by generating a 15-p-nitrophenylcarbonate and then reacting it with the tetra-n-butylammonium salt of alendronic acid to give 9 (Scheme 1). Notably, while alendronate itself has little or no solubility in any solvent other than water, the monotetra-n-butylammonium salt is freely soluble in dry DMF which allows one to work in non-aqueous environments. The ethyl ester of 7 (or a conjugate derived from 7) was expected to hydrolyze rapidly to liberate the free carboxylic acid upon exposure to rat plasma esterases to liberate the free acid in vitro and in vivo and this was confirmed by model incubation of 7 in rat plasma. The novel tetrazole conjugate 11 was synthesized by exposing the mercury salt of 6 to iodomethyl-4-nitrophenylcarbonate 12 to form the methylene carbonate as a mixture of separable regioisomers (10a and 10b), favouring the 2,5-disubstituted tetrazole. Reaction with tetra-n-butylammonium alendronate gave conjugates 11a and 11b (Scheme 2). Purification of these conjugates was tedious, requiring careful extraction, ion-exchange chromatography to remove the tetra-n-butylammonium ion and final isolation by reverse-phase chromatography. While the compounds were initially prepared and characterized separately, the conjugates 11a and 11b were subsequently prepared and evaluated as the mixture.
These conjugates were first examined for their stability in rat plasma. If they were not sufficiently robust to survive delivery to bone after IV injection they clearly would not be suitable candidates for further development. 100 lg/mL samples of conjugate were incubated in fresh rat plasma at 37°C. Aliquots were removed after various time periods and were diluted with equal volumes of acetonitrile and centrifuged to remove precipitated proteins and the concentrations of liberated EP4 agonists 5 and 6 was monitored using LC/MS. It was found that the C-15 hydroxyl conjugate 9 was stable over 96 h under these conditions while tetrazole conjugate 11 was liberated slowly (ca. 5% after 96 h). Both conjugates hydrolyzed completely to liberate 5 or 6 respectively when treated at pH 10 for a few minutes. As it was expected that uptake into bone would be relatively facile should they survive in the circulatory system, both conjugates were taken forward for in vivo evaluation.
In order to measure the in vivo uptake of the conjugates and the release of the EP4 agonists from bone it was necessary to radiolabel the conjugates. By dosing a conjugate of known specific activity labelled on the EP4 agonist portion, the initial uptake into bone and 
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There is an important medical need for effective therapies to redress the general bone loss associated with advanced osteoporosis. Prostaglandin E2 and related EP4 receptor agonists have been shown to stimulate bone regrowth but their use has been limited by systemic side effects. Herein is described the design and synthesis of novel dual-action bone-targeting conjugate pro-drugs where two classes of active agents, a bone growth stimulating prostaglandin E2 EP4 receptor subtype agonist (5 or 6) and a bone resorption inhibitor bisphosphonate, alendronic acid (1), are coupled using metabolically labile carbamate or 4-hydroxyphenylacetic acid based linkers. Radiolabelled conjugates 9, 11a/b and 25 were synthesized and evaluated in vivo in rats for uptake of the conjugate into bone and subsequent release of the EP4 agonists over time. While conjugate 11a/b was taken up (9.0% of initial dose) but not released over two weeks, conjugates 9 and 25 were absorbed at 9.4% and 5.9% uptake of the initial dose and slowly released with half-lives of approximately 2 weeks and 5 days respectively. These conjugates were well tolerated and offer potential for sustained release and dual synergistic activity through their selective bone targeting and local release of the complimentary active components. Ó 2012 Elsevier Ltd. All rights reserved.
Introduction
Osteoporosis is a degenerative disease of the bone resulting from an imbalance between the bone-resorptive action of osteoclasts and the bone-generating action of osteoblasts. As a disease of the elderly, this imbalance leads to a slow loss of bone density and a greatly increased risk of bone fracture in this population.
The treatment of osteoporosis can be accomplished in two ways: by inhibiting the rate of bone resorption or enhancing the rate of growth of new bone. The standard antiresorptive treatments for this disease are bisphosphonate drugs such as alendronic acid 1, RANK ligand inhibitors such as denosumab and selective estrogen receptor modulators (SERMs). A new class of antiresorptive agent, cathepsin-K inhibitors such as odanacatib 2 1 (Fig. 1) , are in late stage development and may offer improved antiresorptive therapy. The bisphosphonate functionality in alendronate mimics the structure of pyrophosphate, both of which chelate strongly with calcium. As bone is the largest reservoir of calcium in the human body bisphosphonates are site-selective for accumulation there, and bisphosphonate antiresorptives tend to have very long half-lives because of this.
While these therapies represent vital tools in treating osteoporosis by halting further progression of the disease, it is normally only treated pharmacologically after considerable bone loss has already taken place. Thus, it is also of interest to stimulate the growth of new bone in place of that which has been lost. To this end, parathyroid hormone can be used to stimulate bone growth but its use has been limited as treatment requires a daily subcutaneous injection and it has been associated with osteosarcoma. 2 It has also been shown that prostaglandin E2 (PGE2, 3) can induce bone growth in animals and humans when given via systemic injection 3 or site-specific delivery to bone 4 and studies have indicated that this activity is mediated by activation of the PGE2 EP4 Contents lists available at SciVerse ScienceDirect
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journal homepage: www.elsevier.com/locate/bmc was expected tobe a relatively facile process. The synthesis of this linker began by preparing the pentafluorophenyl-activated ester 22 from known compound 21. 14 Acylation of the C-15 hydroxyl of 7 again proceeded smoothly to afford 23, which was converted to carbonate 24 in 2 steps. Using an alternative set of coupling conditions that greatly facilitate purification of the final bisphosphonate products, we were pleased to see that the desired conjugate was isolated in high yield as triethylamine salt 25 (Scheme 4). With a second generation conjugate in hand the stage was set for its' in vitro and in vivo evaluation for uptake and release from bone. After initially determining that conjugate 25 was sufficiently stable for IV injection (6% hydrolysis after 24 h in rat plasma at 37°C) it was dosed into rats following the protocol used for our first round of in vivo testing. Although the uptake of 25 into bone was not quite as efficient as seen with conjugates 9 and 11 (5.9% uptake 6 h after dosing), our hypothesis that the 4-hydroxyphenylacetic acid based linkage would provide a more labile system was confirmed when we found the bound radiolabelled EP4 agonist was released with a half-life of approximately 5 days (see Fig. 3 ). This allows calculation that a 5 mg/kg dose of 25 should provide sustained release of 5 at a rate of ca. 15 lg/kg/d or about three times more than achieved with conjugate 9 for the same dose and comparable to the rate of release of PGE2 previously shown to be efficacious in an OVX rat model of reversal of bone loss. 4 While this experiment does not directly demonstrate the rate at which the 4-hydroxyphenyl-acetic acid moiety is hydrolyzed from the bisphosphonate moiety, we are confident that considering the known lability of phenolic carbamates and the extremely long halflife of alendronic acid when bound to bone, the anti-resorptive effects of the bisphosphonate should also be observed via slow release.
In conclusion, we have developed a versatile method for the preparation of dual action bone targeting pro-drug conjugates by coupling the primary amino group of anti-resorptive bisphosphonates such as alendronic acid 1 and hydroxyl containing EP4 receptor selective agonists such as 5 or 6. While the first iteration of carbamate-based conjugates proved too stable in vivo the interposition of a dual-functional coupling group, 4-hydroxyphenylacetic acid proved successful. Scale-up of the synthesis of the optimized conjugate 25 is underway and results of longer term in vivo bone growth experiments to determine ultimate biological efficacy of this compound compared to the separate components in established models on bone growth stimulation will be reported in the near future.
3. Experimental section 3.1. General methods 1 H and 13 C NMR spectra were recorded with a Bruker Avance II 600 MHz spectrometer using a TCI cryoprobe, an Avance III 500 MHz spectrometer using a TXI inverse probe, or an Avance III 400 MHz spectrometer using a BBOF + ATM probe. 31 P NMR spectra were recorded on the Avance 600 MHz spectrometer referenced to inorganic phosphate (external). All assignments were confirmed with the aid of two-dimensional 1 H, 1 H (COSY) and 1 H, 13 C (HSQC) experiments. Processing of the spectra was performed with Mestrelab Research MestRecNova version 6.0.4-5850 software. The highresolution mass spectra were recorded in positive ion-mode with an ESI ion source on an Agilent Time-of-Flight LC/MS mass spectrometer. Analytical thin-layer chromatography (TLC) was performed on aluminum plates pre-coated with silica gel 60F-254 as the adsorbent. The developed plates were air-dried, exposed to UV light and/or dipped in KMnO4 solution and heated. Column chromatography was performed with silica gel 60 (230-400 mesh).
All animal experiments were carried out in compliance with animal care guidelines and policies of the Canadian Council on Animal Care and under protocols approved by the Simon Fraser University Animal Care Committee. 
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